Stockreport

Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue [Seeking Alpha]

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF Non-Jakafi segments grew over 50% YoY in 2025, with management guiding these products to reach $3–4B by 2030, supporting long-term growth. Consensus models an aggress [Read more]